Antimicrobial Prophylaxis in Adults (2024)

1. Osmon DR. Antimicrobial prophylaxis in adults. Mayo Clin Proc. 2000;75:98-109 [PubMed] [Google Scholar]

2. Crabtree TD, Pelletier SJ, Gleason TG, Pruett TL, Sawyer RG. Clinical characteristics and antibiotic utilization in surgical patients with Clostridium difficile-associated diarrhea. Am Surg. 1999;65(6):507-511 [PubMed] [Google Scholar]

3. US Food and Drug Administration (FDA) Information for healthcare professionals: fluoroquinolone antimicrobial drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]: tendonitis risk black box warning, 7/8/2008; 2008. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm089652.htm Accessed May 20, 2011

4. Gerber MA, Baltimore R, Eaton C, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Diseases in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation. 2009;119:1541-1551 [PubMed] [Google Scholar]

5. Baddour LM. Cellulitis and erysipelas. In: Baron EL, ed. UpToDate; 2008. [Google Scholar]

6. Pasternack MS, Swartz MN. Cellulitis, necrotizing fasciitis, and subcutaneous tissue infections. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practices of Infectious Diseases. Vol 1 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:1289-1312 [Google Scholar]

7. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-1406 [PubMed] [Google Scholar]

8. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant S aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e8-e55 [PubMed] [Google Scholar]

9. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA. 1988;260:2682-2685 [PubMed] [Google Scholar]

10. Baddour LM, Epstein AE, Erickson CC, et al.; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Interdisciplinary Council on Quality of Care and Outcomes Research Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010;121:458-477 [PubMed] [Google Scholar]

11. Centers for Disease Control and Prevention (CDC) Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997;46(RR-5):1-10 [PubMed] [Google Scholar]

12. Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(12):1499-1539 [PubMed] [Google Scholar]

13. Stapleton A, Stamm W. Prevention of urinary tract infection. Infect Dis Clin North Am. 1997;11:719-733 [PubMed] [Google Scholar]

14. Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med. 2001;135:9-16 [PubMed] [Google Scholar]

15. Melekos MD, Asbach HW, Gerharz E, Zarakovitis IE, Weingaertner K, Naber KG. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol. 1997;157:935-939 [PubMed] [Google Scholar]

16. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087-2107 [PubMed] [Google Scholar]

17. Moran GJ, Talan DA, Abrahamian FM. Antimicrobial prophylaxis for wounds and procedures in the emergency department. Infect Dis Clin North Am. 2008;22:117-143 [PubMed] [Google Scholar]

19. Goldstein EJC. Bites. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. Vol 2 Philadelphia, PA: Churchill Livingstone Elsevier; 2010:3911-3915 [Google Scholar]

20. Centers for Disease Control and Prevention (CDC) Recommended antimicrobial agents for treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Morb Mortal Wkly Rep. 2005;54:1-15 [PubMed] [Google Scholar]

21. Antiviral drugs for influenza. Med Lett Drugs Ther. 2009;51(1325):89-92 [PubMed] [Google Scholar]

22. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children: diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003-1032 [PMC free article] [PubMed] [Google Scholar]

23. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea [published correction appears in Ann Intern Med. 2005;143(3):239]. Ann Intern Med. 2005;142(10):805-812 [PubMed] [Google Scholar]

24. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats [editorial]. J Infect Dis. 2011;203:6-10 [PMC free article] [PubMed] [Google Scholar]

25. Feinstein AR, Wood HF, Epstein JA, Taranta A, Simpson R, Tursky E. A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children: results of the first three years of the study, including methods for evaluating the maintenance of oral prophylaxis. N Engl J Med. 1959;260:697-702 [PubMed] [Google Scholar]

26. Jorup-Rönström C, Briotton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection. 1987;15(2):105-106 [PubMed] [Google Scholar]

27. Sjöblom AC, Eriksson B, Jorup-Rönström C, Karkkonen K, Lindqvist M. Antibiotic prophylaxis in recurrent erysipelas. Infection. 1993;21:390-393 [PubMed] [Google Scholar]

28. Wang Jh, Liu Yc, Cheng Dl, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis. 1997;25:685-689 [PubMed] [Google Scholar]

30. Centers for Disease Control and Prevention (CDC) Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2005;54 (RR-7):1-10 [Google Scholar]

31. Price VE, Blanchette VS, Ford-Jones EL. The prevention and management of infections in children with asplenia or hyposplenia. Infect Dis Clin North Am. 2007;21(3):697-710, viii-ix [PubMed] [Google Scholar]

32. American Academy of Pediatrics Committee on Infectious Diseases Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106(2, pt 1):362-366 [PubMed] [Google Scholar]

33. Montalembert M, Lenoir G. Antibiotic prevention of pneumococcal infections in asplenic hosts: admission of insufficiency. Ann Hematol. 2004;83:18-21 [PubMed] [Google Scholar]

34. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. Vol 1 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:957-985 [Google Scholar]

35. Lee BB, Simpson JM, Craig JC, Bhuta T. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2007;(4):CD003265 [PubMed] [Google Scholar]

36. Raz R, Chazan B, Dan M. Cranberry juice and urinary tract infection. Clin Infect Dis. 2004;38:1413-1419 [PubMed] [Google Scholar]

37. Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2008;(1):CD001321 [PubMed] [Google Scholar]

38. Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrotta C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209 [PMC free article] [PubMed] [Google Scholar]

39. Raz R, Stamm WE. A controlled trial of intravagin*l estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329:753-756 [PubMed] [Google Scholar]

40. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Soares-Weiser K, Uribe M. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;(9):CD002907 [PMC free article] [PubMed] [Google Scholar]

41. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12:716-724 [PubMed] [Google Scholar]

42. Novella M, Sola R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology. 1997;25:532-536 [PubMed] [Google Scholar]

43. Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology. 1995;22:1171-1174 [PubMed] [Google Scholar]

44. Singh N, Gayowski T, Yu V, Wagener M. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med. 1995;122:595-598 [PubMed] [Google Scholar]

45. Cohen MJ, Sahar T, Benenson S, Elinav E, Brezis M, Soares-Weiser K. Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding. Cochrane Database Syst Rev. 2009;(2):CD004791 [PubMed] [Google Scholar]

46. Das A. A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis. Am J Gastroenterol. 1998;93:1895-1900 [PubMed] [Google Scholar]

47. Baron MJ, Madoff LC. Pancreatic infection. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. Vol 1 Philadelphia, PA: Churchill Livingstone Elsevier; 2010:1045-1053 [Google Scholar]

48. Villatoro E, Mulla M, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev. 2010;(5):CD002941 [PMC free article] [PubMed] [Google Scholar]

49. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101:2379-2400 [PubMed] [Google Scholar]

50. Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007;132(5):2022-2044 [PubMed] [Google Scholar]

51. Kizer K. Animal bites. In: Gorbach S, Bartlett J, Blacklow N, eds. Infectious Diseases. 2nd ed. Philadelphia, PA: Saunders; 1998:1559-1563 [Google Scholar]

52. Talan DA, Citron DM, Abrahamian FM, Moran GJ, Goldstein EJC. Bacteriologic analysis of infected dog and cat bites. N Engl J Med. 1999;340:85-92 [PubMed] [Google Scholar]

53. Cummings P. Antibiotics to prevent infection in patients with dog bite wounds: a meta-analysis of randomized trials. Ann Emerg Med. 1994;23:535-540 [PubMed] [Google Scholar]

54. Fleisher GR. The management of bite wounds. N Engl J Med. 1999;340:138-140 [PubMed] [Google Scholar]

55. Dellinger EP, Wertz MJ, Miller SD, Coyle MB. Hand infections: bacteriology and treatment: a prospective study. Arch Surg. 1988;123:745-750 [PubMed] [Google Scholar]

56. Centers for Disease Control and Prevention (CDC) Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2006;55:1-34 [Google Scholar]

57. Centers for Disease Control and Prevention (CDC) Tetanus and pertussis vaccination coverage among adults aged ≥18 years — United States, 1999 and 2008. MMWR Morb Mortal Wkly Rep. 2010;59:1302-1306 [PubMed] [Google Scholar]

58. Centers for Disease Control and Prevention (CDC) Final 2009 reports of nationally notifiable diseases. MMWR Morb Mortal Wkly Rep. 2010;59:1025,1035 [Google Scholar]

59. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011;60:13-15 [PubMed] [Google Scholar]

60. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) Provisional recommendations for health care personnel on use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) and use of postexposure antimicrobial prophylaxis. http://www.cdc.gov/vaccines/recs/provisional/downloads/use-of-Tdap-in-hcp.pdf Accessed May 20, 2011

61. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736-1754 [PubMed] [Google Scholar]

62. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780-785 [PubMed] [Google Scholar]

63. Steckelberg JM, Osmon DR. Prosthetic joint infections. In: Waldvogel FA, Bisno AL, eds. Infections Associated With Indwelling Medical Devices. 3rd ed. Washington, DC: American Society for Microbiology; 2000:173-209 [Google Scholar]

64. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351:1645-1654 [PubMed] [Google Scholar]

65. Ahlberg A, Carlsson A, Lindberg L. Hematogenous infection in total joint replacement. Clin Orthop Relat Res. 1978;137:69-75 [PubMed] [Google Scholar]

66. Bengtson S, Blomgren G, Knutson K, Wigren A, Lidgren L. Hematogenous infection after knee arthroplasty. Acta Orthop Scand. 1987;58:529-534 [PubMed] [Google Scholar]

67. Deacon JM, Pagilaro AJ, Zelicof SB, Horowitz HW. Current concepts review: prophylactic use of antibiotics for procedures after total joint replacement. J Bone Joint Surg Am. 1996;78(11):1755-1770 [PubMed] [Google Scholar]

68. Uçkay I, Pittet D, Bernard L, Lew D, Perrier A, Peter R. Antibiotic prophylaxis before invasive dental procedures in patients with arthroplasties of the hip and knee. J Bone Joint Surg Br. 2008;90:833-838 [PubMed] [Google Scholar]

69. Lockhart PB, Loven B, Brennan MT, Fox PC. The evidence base for the efficacy of antibiotic prophylaxis in dental practice. J Am Dent Assoc. 2007;138:458-474 [PubMed] [Google Scholar]

70. Berbari EF, Osmon DR, Carr A, et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. Clin Infect Dis. 2010;50:8-16 [PubMed] [Google Scholar]

71. Wahl M. Myths of dental-induced prosthetic joint infections. Clin Infect Dis. 1995;20:1420-1425 [PubMed] [Google Scholar]

72. Lockhart PB, Brennan MT, Fox PC, Norton HJ, Jernigan DB, Strausbaugh LJ. Decision-making on the use of antimicrobial prophylaxis for dental procedures: a survey of infectious disease consultants and review. Clin Infect Dis. 2002;34:1621-1626 [PubMed] [Google Scholar]

73. Hanssen AD, Osmon DR. The use of prophylactic antimicrobial agents during and after hip arthroplasty. Clin Orthop Relat Res. 1999. December;(369):124-138 [PubMed] [Google Scholar]

74. Little JW. Patients with prosthetic joints: are they at risk when receiving invasive dental procedures? Spec Care Dentist. 1997;17(5):153-160 [PubMed] [Google Scholar]

75. Sandhu SS, Lowry JC, Reuben SF, Morton ME. Who decides on the need for antibiotic prophylaxis in patients with major arthroplasties requiring dental treatment: is it a joint responsibility? Ann R Coll Surg Engl. 1997;79:143-147 [PMC free article] [PubMed] [Google Scholar]

76. American Dental Association; American Association of Orthopedic Surgeons Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc. 2003;134(7):895-898 [PubMed] [Google Scholar]

77. American Association of Orthopedic Surgeons (AAOS) Information statement: antibiotic prophylaxis for bacteremia in patients with joint replacements. http://www.aaos.org/about/papers/advistmt/1033.asp Accessed May 20, 2011 [PubMed]

78. Oliver G, Lowry A, Vernava A, et al.; Standards Task Force; American Society of Colon and Rectal Surgeons Practice parameters for antibiotic prophylaxis—supporting documentation. Dis Colon Rectum. 2000;43(9):1194-1200 [PubMed] [Google Scholar]

79. ASGE Standards of Practice Committee Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc. 2008;67(6):791-798 [PubMed] [Google Scholar]

80. American Urological Association; American Academy of Orthopaedic Surgeons Antibiotic prophylaxis for urological patients with total joint replacements. J Urol. 2003;169:1796-1797 [PubMed] [Google Scholar]

81. Wolf JS, Jr, Bennett C, Dmochowski R, Hollenbeck B, Pearle M, Schaeffer A. Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis. Linthicum, MD: American Urological Association; 2007:1-44 http://www.auanet.org/content/media/antimicroprop08.pdf Accessed May 20, 2011 [PubMed] [Google Scholar]

83. Caeiro JP, DuPont HL. Management of travelers' diarrhoea. Drugs. 1998;56(1):73-81 [PubMed] [Google Scholar]

84. Passaro DJ, Parsonnet J. Advances in the prevention and management of traveler's diarrhea. Curr Clin Top Infect Dis. 1998;18:217-236 [PubMed] [Google Scholar]

85. Ansdell VE, Ericsson CD. Prevention and empiric treatment of traveler's diarrhea. Med Clin North Am. 1999;83:945-973 [PubMed] [Google Scholar]

86. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin Inf Dis. 2002;34(5):628-633 [PubMed] [Google Scholar]

87. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am. 1976;58:453-458 [PubMed] [Google Scholar]

88. Hauser CJ, Adams CA, Jr, Eachempath SR. Prophylactic antibiotic use in open fractures: an evidence-based guideline. Surg Infect (Larchmt). 2006;7(4):379-405 [PubMed] [Google Scholar]

89. Luchette FA, Bone LB, Born CT, et al.; Eastern Association for the Surgery of Trauma (EAST) Working Group Practice management guidelines for prophylactic antibiotic use in open fractures. Published 1998 Updated in 2009. http://www.east.org/tpg/OpenFxUpdate.pdf Accessed May 20, 2011

90. ACOG Committee on Practice Guidelines—Gynecology Gynecologic Herpes simplex virus infections. Obstet Gynecol. 2004;104(5, pt 1):1111-1117 [PubMed] [Google Scholar]

91. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC) Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110 [PubMed] [Google Scholar]

92. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341(18):1336-1343 [PubMed] [Google Scholar]

93. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999;282(1):31-35 [PubMed] [Google Scholar]

94. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC) Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24 [PubMed] [Google Scholar]

95. Fiore AE, Shay DK, Broder K, et al.; Centers for Disease Control and Prevention (CDC) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57(RR-7):1-60 [PubMed] [Google Scholar]

96. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 1993;6(4):428-442 [PMC free article] [PubMed] [Google Scholar]

97. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29(11):996-1011 [PubMed] [Google Scholar]

98. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR; Hospital Infection Control Practices Advisory Committee Guidelines for the prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol. 1999;20(4):250-278 [PubMed] [Google Scholar]

99. American Society of Health-System Pharmacists ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 1999;56(18):1839-1888 [PubMed] [Google Scholar]

100. Antimicrobial Prophylaxis for Surgery. Treatment Guidelines from the Medical Letter. 2009. June; 7(82):47-52 [PubMed] [Google Scholar]

101. Sexton DJ. Carbapenems for surgical prophylaxis [editorial]? N Engl J Med. 2006;355(25):2693-2695 [PubMed] [Google Scholar]

102. Bratzler DW, Houck PM. Antimicrobial Prophylaxis for Surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38:1706-1715 [PubMed] [Google Scholar]

103. Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR. The Society of Thoracic Surgeons Practice Guideline Series: antibiotic prophylaxis in cardiac surgery; Part I: duration. Ann Thorac Surg. 2006;81:397-404 [PubMed] [Google Scholar]

104. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons Practice Guideline Series: antibiotic prophylaxis in cardiac surgery; Part II: antibiotic choice. Ann Thorac Surg. 2007;83:1569-1576 [PubMed] [Google Scholar]

105. de Oliveira JC, Martinelli M, Nishioka SA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large prospective, randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2(1):29-34 [PubMed] [Google Scholar]

106. Sohail MR, Uslan DZ, Khan AH, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis. 2007;45(2):166-173 [PubMed] [Google Scholar]

107. Dobay KJ, Freier D, Albear P. The absent role of prophylactic antibiotics in low-risk patients undergoing laparoscopic cholecystectomy. Am Surg. 1999;65(3):226-228 [PubMed] [Google Scholar]

108. Higgins A, London J, Charland S, et al. Prophylactic antibiotics for elective laparoscopic cholecystectomy: are they necessary? Arch Surg. 1999;134(6):611-613 [PubMed] [Google Scholar]

109. Meijer WS, Schmitz PI, Jeekel J. Meta-analysis of randomized, controlled clinical trials of antibiotic prophylaxis in biliary tract surgery. Br J Surg. 1990;77(3):282-290 [PubMed] [Google Scholar]

110. Baum ML, Anish DS, Chalmers TC, Sacks HS, Smith H, Jr, fa*gerstrom RM. A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. N Engl J Med. 1981;305(14):795-799 [PubMed] [Google Scholar]

111. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Gynecology ACOG Practice Bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol. 2009;113(5):1180-1189 [PubMed] [Google Scholar]

112. American College of Obstetricians and Gynecologists (ACOG) Committee Antimicrobial prophylaxis for cesarean delivery: timing of administration: Obstet Gynecol. 2010;116(3):791-792 [PubMed] [Google Scholar]

113. Simo R, French G. The use of prophylactic antibiotics in head and neck oncological surgery. Curr Opin Otolaryngol Head Neck Surg. 2006;14:55-61 [PubMed] [Google Scholar]

114. Weber RS. Wound infection in head and neck surgery: implications for perioperative antibiotic treatment. Ear Nose Throat J. 1997;76(11):790-791, 795-798 [PubMed] [Google Scholar]

115. Barker FG., II Efficacy of prophylactic antibiotics for craniotomy: a meta-analysis. Neurosurgery. 1994;35(3):484-490 [PubMed] [Google Scholar]

116. Barker FG., II Efficacy of prophylactic antibiotics in spinal surgery: a meta-analysis. Neurosurgery. 2002;51(2):391-400 [PubMed] [Google Scholar]

117. Barker FG., II Efficacy of prophylactic antibiotics against meningitis after craniotomy: a meta-analysis. Neurosurgery. 2007;60(5):887-894 [PubMed] [Google Scholar]

118. Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy Antimicrobial prophylaxis in neurosurgery and after head injury. Lancet. 1994;344(8936):1547-1551 [PubMed] [Google Scholar]

119. Haines SJ, Walters BC. Antibiotic prophylaxis for cerebrospinal fluid shunts: a metanalysis. Neurosurgery. 1994;34(1):87-92 [PubMed] [Google Scholar]

120. Langley JM, LeBlanc JC, Drake J, Millner R. Efficacy of antimicrobial prophylaxis in placement of cerebrospinal fluid shunts: meta-analysis. Clin Infect Dis. 1993;17(1):98-103 [PubMed] [Google Scholar]

121. Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts: a systematic review. J Neurosurg Pediatr. 2008;1:48-56 [PubMed] [Google Scholar]

122. DeCroos FC, Afshari NA. Perioperative antibiotics and anti-inflammatory agents in cataract surgery. Curr Opin Ophthalmol. 2008;19:22-26 [PubMed] [Google Scholar]

123. Liesegang TJ. Perioperative antibiotic prophylaxis in cataract surgery [published correction appears in Cornea. 2000;19(1):123]. Cornea. 1999;18(4):383-402 [PubMed] [Google Scholar]

124. Gillespie WJ, Walenkamp G. Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures. Cochrane Database Syst Rev. 2001;(1): CD000244 [PubMed] [Google Scholar]

125. Prokuski L. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg. 2008;16:283-293 [PubMed] [Google Scholar]

126. Homer-Vanniasinkam S. Surgical site and vascular infections: treatment and prophylaxis. Int J Infect Dis. 2007;11(suppl 1):S17-S22 [PubMed] [Google Scholar]

127. Stewart AH, Eyers PS, Earnshaw JJ. Prevention of infection in peripheral arterial reconstruction: a systematic review and meta-analysis. J Vasc Surg. 2007;46:148-155 [PubMed] [Google Scholar]

128. Kluytmans JA, Mouton JW, VandenBergh MF, et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol. 1996;17(12):780-785 [PubMed] [Google Scholar]

129. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346:1871-1877 [PubMed] [Google Scholar]

130. Rey JR, Axon A, Budzynsak A, Kruse A, Nowak A. Guidelines of the European Society of Gastrointestinal Endoscopy (ESGE) antibiotic prophylaxis for gastrointestinal endoscopy. Endoscopy. 1998;30(3):318-324 [PubMed] [Google Scholar]

131. Gernaat-van der Sluis AJ, Hoogenboom-Verdegaal AMM, Edixhoven PJ, Spies-van Rooijen NH. Prophylactic mupirocin could reduce orthopedic wound infections: 1,044 patients treated with mupirocin compared with 1,260 historical controls. Acta Orthop Scand. 1998;69:412-414 [PubMed] [Google Scholar]

132. Centers for Disease Control and Prevention (CDC) Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recom Rep. 1995;44(RR-12):1-13 [PubMed] [Google Scholar]

133. Centers for Disease Control and Prevention (CDC) Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep. 1997;46(27):626-628; 635 [PubMed] [Google Scholar]

134. Centers for Disease Control and Prevention (CDC) Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan, 1996. MMWR Morb Mortal Wkly Rep. 1997;46(27):624-626 [PubMed] [Google Scholar]

135. Centers for Disease Control and Prevention (CDC) Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997 [published correction appears in MMWR Morb Mortal Wkly Rep. 1997;46:851]. MMWR Morb Mortal Wkly Rep. 1997;46(33):765-766 [PubMed] [Google Scholar]

136. Southorn PA, Plevak DJ, Wright AJ, Wilson WR. Adverse effects of vancomycin administered in the perioperative period. Mayo Clin Proc. 1986;61:721-724 [PubMed] [Google Scholar]

137. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery. 1961;50:161-168 [PubMed] [Google Scholar]

138. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical wound infection. N Engl J Med. 1992;326(5):281-286 [PubMed] [Google Scholar]

139. Zanetti G, Giardina R, Platt R. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis. 2001;7:828-831 [PMC free article] [PubMed] [Google Scholar]

141. Wright TI, Baddour LM, Berbari EF, et al. Antibiotic prophylaxis in dermatologic surgery: advisory statement 2008. J Am Acad Dermatol. 2008;59:464-473 [PubMed] [Google Scholar]